A collaboration has been initiated between Cullinan Oncology and MAB Discovery that is focused on the development of novel antibody-based therapeutics.
Collaboration
“We are excited to enter into this collaboration as the MABD development engine provides us with access to highly differentiated monoclonal antibodies,” affirmed Patrick Baeuerle, Cullinan's chief scientific officer, Biologics. “Our first programme is a novel agonistic antibody that has the potential to be a pillar of future immuno-oncology and standard treatments. We look forward to working with Stephan Fischer and the MABD team to execute the development plan and progress the asset into the clinic.”
Dr Stephan Fischer, CEO of MAB Discovery, stated: “We are delighted to partner with Patrick and the Cullinan team, and look forward to understanding how the unique attributes of our rabbit-based platform translate into highly differentiated antibodies that have the potential to significantly advance patient outcomes.”
Under the terms of this collaboration, MAB Discovery’s rabbit-based antibody discovery platform will be used by Cullinan Oncology to develop therapeutics. There will be the potential for MAB Discovery to receive cash payments once specified milestones have been achieved in addition to an upfront equity interest in Cullinan Wittelsbach — a subsidiary of Cullinan Oncology.